-- Study to evaluate potential of novel combination therapy for hormone-receptor-positive, human epidermal growth factor receptor 2-negative (HR+, HER2-) metastatic breast cancer (mBC)
-- Lilly's CDK 4 and CDK 6 inhibitor abemaciclib and Boehringer Ingelheim's IGF mAB BI 836845 have shown promising early phase results in mBC
Lilly and Boehringer Ingelheim Announce Clinical Trial Collaboration in Metastatic Breast Cancer (NYSE:LLY)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.